Avadel Pharmaceuticals plc (AVDL)
NASDAQ: AVDL · IEX Real-Time Price · USD
16.91
+0.35 (2.11%)
Jul 16, 2024, 4:00 PM EDT - Market closed

Company Description

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States.

Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy.

The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.

Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Avadel Pharmaceuticals plc
Avadel Pharmaceuticals logo
Country Ireland
IPO Date Jun 7, 1996
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 154
CEO Gregory J. Divis Jr.

Contact Details

Address:
Block 10-1 Blanchardstown Corporate Park, Ballycoolin
Dublin, L2 15
Ireland
Phone 636-449-1830
Website avadel.com

Stock Details

Ticker Symbol AVDL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001012477
CUSIP Number 05337M104
ISIN Number US05337M1045
SIC Code 2834

Key Executives

Name Position
Gregory J. Divis Jr. Chief Executive Officer and Director
Thomas S. McHugh Senior Vice President, Principal Financial and Accounting Officer and Chief Financial Officer
Richard J. Kim Chief Commercial Officer
Jerad G. Seurer General Counsel and Company Secretary
Gregory J. Davis Vice President of Corporate and Business Development
Mark W. Elrod Vice President of Sales
Angie Woods Vice President of People and Culture
Dr. Jordan S. Dubow M.D. Consultant
Dr. Jason M. Vaughn Senior Vice President of Technical Operations
Jennifer Gudeman PharmD Senior Vice President of Medical and Clinical Affairs

Latest SEC Filings

Date Type Title
Jun 27, 2024 8-K Current Report
Jun 18, 2024 ARS Filing
Jun 18, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Jun 18, 2024 DEF 14A Other definitive proxy statements
May 21, 2024 8-K Current Report
May 17, 2024 S-8 Securities to be offered to employees in employee benefit plans
May 8, 2024 8-K Current Report
May 8, 2024 424B5 Filing
May 8, 2024 10-Q Quarterly Report
May 8, 2024 8-K Current Report